Grant: Engage Grants Program
Dalhousie University
$25,000.00
Development of Microparticles for Enhanced Embolization Therapies
FY 2015-16
Summary
The development of novel biomaterials for medical applications is a challenge that requires advanced
manufacturing techniques. For example, specialized microparticles have the potential to substantially improve
the treatment of diseases such as hepatocellular carcinoma (HCC). Microparticles enable localized therapies
such as transarterial chemoembolization (TACE) to be used in cases where the disease has been diagnosed at
an advanced stage and surgical treatment is not possible. In TACE therapy, which is a minimally-invasive
alternative to surgery, microparticles are utilized as embolic agents. The particles prevent blood flow to tumors
and can also function as a targeted drug delivery system, when preloaded with a suitable drug.
The proposed research is in collaboration with ABK Biomedical Inc., a dynamic medical device start-up
company based in Nova Scotia. They are currently pursuing the development of embolic agents to treat cancers
such as HCC. ABK's products are based on a novel radiopaque embolic bead platform that will enable
clinicians to visually monitor the embolic site both during and post-procedure. They are seeking to extend their
range of TACE products by developing advanced manufacturing techniques for the following novel
biomaterials: (1) polymer-coated glass embolic microspheres to facilitate drug-delivery and (2) polymer-blend
embolic microspheres. Dr. Brooks' research team at Dalhousie University will investigate advanced
manufacturing techniques for the development of a suitable polymer-coating for the glass microspheres and
new polymer-blends for synthesizing radiopaque embolic microspheres.
Program
Engage Grants Program
Recipient
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
488457-2015
Name nom
Brooks, MarianneSuLing
Department département
Process Engineering and Applied Science
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Development of Microparticles for Enhanced Embolization Therapies
Keyword
NSERC
Application summary
The development of novel biomaterials for medical applications is a challenge that requires advanced
manufacturing techniques. For example, specialized microparticles have the potential to substantially improve
the treatment of diseases such as hepatocellular carcinoma (HCC). Microparticles enable localized therapies
such as transarterial chemoembolization (TACE) to be used in cases where the disease has been diagnosed at
an advanced stage and surgical treatment is not possible. In TACE therapy, which is a minimally-invasive
alternative to surgery, microparticles are utilized as embolic agents. The particles prevent blood flow to tumors
and can also function as a targeted drug delivery system, when preloaded with a suitable drug.
The proposed research is in collaboration with ABK Biomedical Inc., a dynamic medical device start-up
company based in Nova Scotia. They are currently pursuing the development of embolic agents to treat cancers
such as HCC. ABK's products are based on a novel radiopaque embolic bead platform that will enable
clinicians to visually monitor the embolic site both during and post-procedure. They are seeking to extend their
range of TACE products by developing advanced manufacturing techniques for the following novel
biomaterials: (1) polymer-coated glass embolic microspheres to facilitate drug-delivery and (2) polymer-blend
embolic microspheres. Dr. Brooks' research team at Dalhousie University will investigate advanced
manufacturing techniques for the development of a suitable polymer-coating for the glass microspheres and
new polymer-blends for synthesizing radiopaque embolic microspheres.